Creative Biolabs possesses unchallenged experience in synthesis of bispecific antibody (BsAbs) and is committed to providing customers desired BsAbs with low immunogenicity and high affinity for both academic and clinical applications.
In ophthalmology, many diseases are related to vascular abnormalities. For example, diabetic retinopathy (DR) and age related macular degeneration (AMD), which are the leading causes of visual loss, are due to abnormal retinal or choroidal neovascularization, respectively. Interference with receptor signaling pathways serves as a therapeutic principle in ophthalmology. A popular strategy is to block signaling pathways involved in angiogenesis or vasculogenesis in eyes. BsAbs can target two pathways at the same time or block the same pathway at two points. Therefore BsAbs are great drug formats for next-generation therapeutics in the pharmaceutical industry for ocular disease treatment.
Figure 1. Schematic diagram shows the VEGF family and receptor interactions. This diagram shows the specific binding of VEGFs to their endothelial receptors. (Bry, M., 2014)
The retina consists of well-defined layers of fragile cells and elements, and even very small disturbances (such as vascular abnormalities) can lead to significant loss of visual function. Different strategies have been developed to stop new vessel growth and preserve central vision in these diseases. The vascular endothelial growth factor (VEGF) is a major promoter of vessel growth. Therefore VEGF and VEGF receptor tyrosine kinases are targets of interest. Like the VEGF receptor tyrosine kinases, the Tie-2 receptor is also selectively expressed in the endothelium. Angiopoietin-2 (Ang2) is a ligand of this receptor and is suggested to promote angiogenesis in conjunction with VEGF.
Different formats of BsAbs are under study in hopes of blocking factors such as VEGF and Ang2. Due to the structure and characters of eyes, drugs that are small and with simple compositions are preferred for use in ophthalmology, as they have shorter half-lives and lower systemic toxicity. CrossMab molecule RG7716 is a BsAb that recognizes VEGFA and Ang2 factors. It reduces angiogenesis in AMD and is in phase 1 trial for wet AMD patients. Other promising BsAb formats include Fab fragments, bispecific intrabody, scFv fragments, dual action Fab BsAb (DAF BsAb).
Figure 2. Examples of various forms of the BsAbs designed for ocular disease treatment. (Le Couter, J., 2014)
Creative Biolabs offers customers high-quality BsAbs based on our novel and advanced technology platforms. Our experienced experts in the research team can design suitable BsAbs and creative strategies to promote your scientific and clinical research in ophthalmology.
1. Bry, M.; et al. Vascular endothelial growth factor-B in physiology and disease. Physiological reviews. 2014, 94(3): 779-794.
2. Le Couter, J.; Scheer, J. M. Bispecific therapeutics for ophthalmic indications: target selection and the optimal molecular format. Expert Review of Ophthalmology. 2014, 9(3): 217-225.